FDA fast-tracks Israeli tissues infection treatment

Israeli bio-tech Atox Bio announced that the US Food and Drug Administration has granted fast track designation to its lead product AB103, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI). Currently, there are no approved treatments for NSTI, which has a high mortality rate.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *